Phase I: Safety and Tolerance of Lactobactocillus reuteri in Adults
Phase I: Safety and Tolerance of Lactobactocillus reuteri in Adults
批准号:
7663878
负责人:
JON Marc RHOADS
金额:
$22.83万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-08-01 至 2011-07-31
关键词:
Abdominal colicAdultAffectBacteriaBasic ScienceCarbohydratesChildClinical ResearchClostridiumColonCommunitiesComplementary and alternative medicineComplexCryingDataDesire for foodDiarrheaExploratory/Developmental GrantFDA approvedFecesFutureGasesGoalsHealthHydrogenInfantInflammatory disease of the intestineIntestinal DiseasesIntestinesInvestigationIrritable Bowel SyndromeLaboratoriesLactobacillusLactobacillus casei rhamnosusMissionModificationNIH Program AnnouncementsNational Center for Complementary and Alternative MedicineOralPhasePilot ProjectsPlacebosProbioticsProcessProductionPublic HealthResearchResearch PersonnelSafetyScienceSleepSymptomsTechnologyTherapeutic InterventionTimeUnited States National Institutes of Healthbasedesigngastrointestinalimprovedin vivoinflammatory marker
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The long-term goals of this laboratory are to elucidate mechanisms of intestinal disease in infants and children and to use basic science to identify rational treatments. Relevant to the mission of NIH, this proposal is designed as a pilot study that will generate and expand the base of in vivo data and direct future research on probiotic therapeutic interventions. Additionally, the investigators aim to utilize state-of-the science technologies to determine the constituents of complex gut microbiotia that are associated with and may contribute to colic, and to examine the impact of probiotics on the composition of the bowel flora.
Colic is defined as crying and fussiness for > 3 hr daily for > 3 d weekly in a child < 3 months old. Currently, there is insufficient evidence supporting any specific treatment to relieve symptoms of infants with colic, with the possible exception of hypoallergenic formula. However, there is evidence that infants with colic produce too much hydrogen gas in the intestine and that their fussiness may be improved by daily administration of certain probiotic (health-promoting) bacteria. Recently, studies in adults with irritable bowel syndrome showed significant improvement with probiotic therapy. Our hypothesis is that infants produce more hydrogen gas because of a different colonic bacterial flora and that modification of this flora with Lactobacillus rhamnosus GG will alter gas production, thereby reducing the time these infants spend crying. We choose to study Lactobacillus rhamnosus GG, one of the two probiotic strains which has received the most investigation in babies with diarrhea. L. rhamnosus GG is FDA-approved and available over-the-counter in the U.S.
Relevance to public health: Colic affects at least 8% of all infants. Our studies would not only provide evidence for whether oral L. rhamnosus GG helps reduce the number of minutes each day with colic; they would also provide evidence of a possible mechanism. Specifically, we will demonstrate if L. rhamnosus GG treatment of infants with colic who have excessive breath hydrogen levels will change the bacterial community in the colon and reduce fecal markers of inflammation. In the process, we will also demonstrate if cultivation-independent analyses of stool will reveal bacterial species associated with colic that were not previously recognized.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Road to discovery for combination probiotic BB-12 with LGG in treating autism spectrum disorder
-
批准号:10657357
-
项目类别:
-
资助金额:$49.2万
-
财政年份:2018
-
负责人:JON Marc RHOADS
-
依托单位:
Road to discovery for combination probiotic BB-12 with LGG in treating autism spectrum disorder
-
批准号:9766942
-
项目类别:
-
资助金额:$41.7万
-
财政年份:2018
-
负责人:JON Marc RHOADS
-
依托单位:
Road to discovery for combination probiotic BB-12 with LGG in treating autism spectrum disorder
-
批准号:10439571
-
项目类别:
-
资助金额:$41.86万
-
财政年份:2018
-
负责人:JON Marc RHOADS
-
依托单位:
Road to discovery for combination probiotic BB-12 with LGG in treating autism spectrum disorder
-
批准号:9969235
-
项目类别:
-
资助金额:$43.49万
-
财政年份:2018
-
负责人:JON Marc RHOADS
-
依托单位:
Safety and Effect of L. reuteri on Biomarkers of Inflammation in Healthy Infants
-
批准号:8650793
-
项目类别:
-
资助金额:$25.98万
-
财政年份:2012
-
负责人:JON Marc RHOADS
-
依托单位:
Safety and Effect of L. reuteri on Biomarkers of Inflammation in Healthy Infants
-
批准号:8304030
-
项目类别:
-
资助金额:$11.4万
-
财政年份:2012
-
负责人:JON Marc RHOADS
-
依托单位:
Effect of Lactobactocillus Rhamnosus GG on Colic Symptoms and Breath Hydrogen
-
批准号:7314788
-
项目类别:
-
资助金额:$4.0万
-
财政年份:2008
-
负责人:JON Marc RHOADS
-
依托单位:
Phase I: Safety and Tolerance of Lactobactocillus reuteri in Adults
-
批准号:7920228
-
项目类别:
-
资助金额:$11.4万
-
财政年份:2008
-
负责人:JON Marc RHOADS
-
依托单位:
Phase I: Safety and Tolerance of Lactobactocillus reuteri in Adults
-
批准号:8259339
-
项目类别:
-
资助金额:$4.9万
-
财政年份:2008
-
负责人:JON Marc RHOADS
-
依托单位:
MECHANISMS OF INTESTINAL CELL MIGRATION
-
批准号:6381820
-
项目类别:
-
资助金额:$7.28万
-
财政年份:2000
-
负责人:JON Marc RHOADS
-
依托单位:
MECHANISMS OF INTESTINAL CELL MIGRATION
-
批准号:6090858
-
项目类别:
-
资助金额:$7.25万
-
财政年份:2000
-
负责人:JON Marc RHOADS
-
依托单位:
GLUTAMINE AND INTESTINAL TRANSPORT AND MUCOSAL GROWTH
-
批准号:3081474
-
项目类别:
-
资助金额:$7.38万
-
财政年份:1990
-
负责人:JON Marc RHOADS
-
依托单位:
GLUTAMINE AND INTESTINAL TRANSPORT AND MUCOSAL GROWTH
-
批准号:2194412
-
项目类别:
-
资助金额:$8.46万
-
财政年份:1990
-
负责人:JON Marc RHOADS
-
依托单位:
GLUTAMINE AND INTESTINAL TRANSPORT AND MUCOSAL GROWTH
-
批准号:3081476
-
项目类别:
-
资助金额:$8.46万
-
财政年份:1990
-
负责人:JON Marc RHOADS
-
依托单位:
GLUTAMINE AND INTESTINAL TRANSPORT AND MUCOSAL GROWTH
-
批准号:3081477
-
项目类别:
-
资助金额:$8.46万
-
财政年份:1990
-
负责人:JON Marc RHOADS
-
依托单位:
GLUTAMINE AND INTESTINAL TRANSPORT AND MUCOSAL GROWTH
-
批准号:3081475
-
项目类别:
-
资助金额:$8.66万
-
财政年份:1990
-
负责人:JON Marc RHOADS
-
依托单位:
海外基金